GlassScriptPhysician profile
Leticia L Cortes
NPI 1124639000
$3,058.77
in general payments reported to CMS, 2019-2025
35 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.25 · 2023: $23.11 · 2024: $1,176 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.87 | 2023-2025 | |
| Biogen, INC. | $361.69 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Pfizer INC. | $287.41 | 2024-2025 | |
| Eisai INC. | $208.42 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $177.54 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Neurocrine Biosciences, INC. | $137.05 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $119.50 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $112.73 | 2024 | Briviact, Rystiggo |
| Genentech USA, INC. | $105.37 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Lundbeck LLC | $100.36 | 2024-2025 | Vyepti |
| Tg Therapeutics, INC. | $94.03 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $76.59 | 2024-2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $62.16 | 2024 | Xeomin |
| Sk Life Science, INC. | $54.12 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $41.47 | 2024-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $38.32 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $30.43 | 2024-2025 | Ongentys 50mg Capsules 30, Crexont |
| Genzyme Corporation | $24.15 | 2024 | |
| Biotronik Nro, INC. | $23.88 | 2025 | Prospera |
| Ns Pharma, INC. | $23.63 | 2025 | Viltepso |
| Vanda Pharmaceuticals INC. | $23.12 | 2025 | Ponvory |
| Tanabe Pharma America, INC. | $23.09 | 2025 | Radicava |
| Octapharma USA, INC. | $21.23 | 2024 | Octagam Immune Globulin (Human) |
| Neurelis, INC. | $19.59 | 2025 | Valtoco |
| Kedrion Biopharma, INC. | $19.52 | 2024 | Koate, Kedrab, Gammaked |
| Springworks Therapeutics, INC. | $18.44 | 2024 | |
| Novo Nordisk INC | $17.41 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.25 | 2025 | Horizant |
| Lilly USA, LLC | $16.96 | 2024 | Emgality |
| Ge Healthcare | $16.45 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.37 | 2024 | Hyqvia |
| Mallinckrodt Hospital Products INC. | $14.24 | 2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $13.83 | 2024 | |
| Janssen Biotech, INC. | $13.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leticia Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.